Innovating Works

NCARDIA BV

Desconocido
PersonalizeAF: Personalized Therapies for Atrial Fibrillation. A Translational Approach NCARDIA BV participó en un H2020: H2020-MSCA-ITN-2019 Atrial Fibrillation (AF) is the most common cardiac arrhythmia affecting more than 6 million Europeans with a cost exceeding 1% of the EU he...
2019-09-11 - 2024-03-31 | Financiado
INSPIRE: INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse... NCARDIA BV participó en un H2020: H2020-MSCA-ITN-2019 New drug candidates often have off-target effects resulting in adverse events, thus representing a major limitation for drug R&D. Safety Pha...
2019-08-19 - 2024-05-31 | Financiado
METACELL-TM: METAbolism analysis made easy for CELL Translational Medicine NCARDIA BV participó en un H2020: H2020-FTIPilot-2016 "The healthcare industry is experiencing unprecedented rates of drug failure, long development times and high costs - because current lab te...
2016-11-17 - 2019-04-30 | Financiado
DeCISIoN: Drug CandIdates ScreenINg NCARDIA BV tramitó un H2020: H2020-SMEInst-2016-2017 Pluriomics is an international Dutch/Belgian biotech company specialised in developing stem cell-based assays for cardiac safety pharmacolog...
2016-06-03 - 2018-12-31 | Financiado
BtRAIN: Brain barriers training NCARDIA BV participó en un H2020: H2020-MSCA-ITN-2015 The brain barriers function to protect the central nervous system (CNS) from neurotoxic compounds. By the same traits they unfortunately blo...
2015-08-03 - 2019-08-31 | Financiado
InForMed: An integrated pilot line for micro fabricated medical devices NCARDIA BV participó en un H2020: ECSEL-2014-2 The goal of the InForMed project is to establish an integrated pilot line for medical devices. The pilot line includes micro-fabrication, as...
2015-07-10 - 2018-09-30 | Financiado
InForMed: An integrated pilot line for micro-fabricated medical devices NCARDIA BV participó en un FP6: ECSEL-2014-2 The goal of the InForMed project is to establish an integrated pilot line for medical devices. The pilot line includes micro-fabrication, as...
2015-06-01 - 2018-09-30 | Financiado
PLURIMES: Pluripotent stem cell resources for mesodermal medicine NCARDIA BV participó en un FP7: Harnessing the capacity of pluripotent stem cells (PSCs) to produce functional cell types with precision and at scale will enable new treatm...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.